Ticker brief
VTRS
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
17
authors 14d
13
crowd 14d
-1.2σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-06 → 2026-10-16 · now +0.00 (−1 bearish … +1 bullish)
Who spoke13
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 4 | -0.05 |
| @FwdQuarter | C | · | 2 | -0.10 |
| @CHItrader | B | -0.22 | 1 | -0.10 |
| @cfromhertz | B | -0.96 | 1 | -0.10 |
| @OMillionaires | C | -0.85 | 1 | -0.10 |
| @MartyChargin | C | -0.56 | 1 | -0.10 |
| @OTR444 | C | +0.13 | 1 | -0.10 |
| @WSJ | A | -0.25 | 1 | -0.10 |
| @OpenOutcrier | C | · | 1 | -0.10 |
| @fwpharma | B | -1.91 | 1 | -0.10 |
| @Tickeron | C | +1.53 | 1 | -0.10 |
| @InvestorIdeas | C | -0.26 | 1 | -0.10 |
| @BarbarianCap | B | +1.97 | 1 | -0.10 |
Recent signals17of 17 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @BiopharmIQ | +0.00 | The tweet lists upcoming October FDA decision dates for three companies. | · | tweet ↗ |
| 2026-10-08 | @BarbarianCap | -0.10 | Viatris will acquire Pacira BioSciences for $1.65 billion. | · | tweet ↗ |
| 2026-10-08 | @BiopharmIQ | -0.10 | Reports PCRX rising about 44% premarket on VTRS buyout news. | · | tweet ↗ |
| 2026-10-08 | @BiopharmIQ | -0.10 | Viatris will acquire Pacira for $36.50 cash per share at a $1.65B equity value and 44.8% premium. | · | tweet ↗ |
| 2026-10-08 | @InvestorIdeas | -0.10 | Viatris agreed to acquire Pacira for $36.50 per share in cash at a $1.65B equity value. | · | tweet ↗ |
| 2026-10-08 | @Tickeron | -0.10 | Viatris agreed to acquire Pacira for $36.50 per share in cash. | · | tweet ↗ |
| 2026-10-08 | @FwdQuarter | -0.10 | VTRS agreed to acquire PCRX for $1.65B in an all-cash tender. | · | tweet ↗ |
| 2026-10-08 | @fwpharma | -0.10 | Viatris agreed to acquire Pacira for $1.65B | · | tweet ↗ |
| 2026-10-08 | @OpenOutcrier | -0.10 | Viatris will acquire Pacira BioSciences for $1.65B, or $36.50 per share in cash. | · | tweet ↗ |
| 2026-10-08 | @WSJ | -0.10 | Viatris agreed to acquire Pacira BioSciences for $1.65B. | · | tweet ↗ |
| 2026-10-08 | @FwdQuarter | -0.10 | VTRS agreed to acquire PCRX for $1.65B cash at $36.50 per share. | · | tweet ↗ |
| 2026-10-08 | @OTR444 | -0.10 | Provides an October 8 momentum watch list with market-cap and company-event notes. | · | tweet ↗ |
| 2026-10-08 | @MartyChargin | -0.10 | Viatris agrees to acquire Pacira for $36.50 cash per share, valuing equity at $1.65B. | · | tweet ↗ |
| 2026-10-08 | @OMillionaires | -0.10 | VTRS will acquire PCRX for $36.50 per share in cash, valuing it at $1.65B. | · | tweet ↗ |
| 2026-10-08 | @cfromhertz | -0.10 | Viatris agrees to acquire Pacira for $1.65B, or $36.50 per share in cash. | · | tweet ↗ |
| 2026-10-08 | @CHItrader | -0.10 | Viatris agrees to acquire Pacira Biosciences for $1.65B in equity value. | · | tweet ↗ |
| 2026-10-06 | @BiopharmIQ | +0.00 | Provides explicit October PDUFA dates for five drug candidates across four issuers. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.